Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Anticoagulation therapy is essential for managing patients with AF, as it helps prevent blood clots that can lead to strokes. Recent research has focused on improving treatment guidelines ...

AstraZeneca's anticoagulant reversal agent Andexxa was ... On the positive side, members of the Cellular, Tissue, and Gene Therapies Advisory Committee agreed that Andexxa was able to prevent ...

Dr. Suresh Vedantham asks Drs. Pavan Kavali and Kristen Sanfilippo about possible benefits of a DVT response team model, ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...